Results of pharmacogenetic testing for personalization of anticoagulant and antiaggregative therapy: 615.275:615.015

Abstract

The data obtained during pharmacogenetic testing for sensitivity to warfarin and clopidogrel resistance were analyzed. Due to pharmacogenetic testing personalized selection of warfarin dose was done: minimum dose was 0,7 mg, maximum dose — 9,8 mg. Pharmacogenetic testing for warfarin dose adjustment allows to individualize approach to its appointment. Frequency of genotypes associated with resistance to clopidogrel among examined patients was 24,1%. These patients required alternative antiaggregant therapy.